NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease

Current Topics in Medicinal Chemistry

Volumn 4, Issue 5, 2004, Pages 561-567

  Yamamura, Takashi ^a   Miyamoto, Katsuichi ^a   Illés, Zsolt ^a   Pál, Endre ^a   Araki, Manabu ^a   Miyake, Sachiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N HEXACOSANOYL 1 O (ALPHA MANNOPYRANOSYL) 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CD1 ANTIGEN; CD1D ANTIGEN; CERAMIDE DERIVATIVE; GAMMA INTERFERON; GLUCOSYLCERAMIDE; GLYCOLIPID; INTERLEUKIN 4; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; SPHINGOLIPID; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL SPECIFICITY; CHEMICAL MODIFICATION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GLYCOSYLATION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; REVIEW; SPONGE (PORIFERA); T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; GLYCOLIPIDS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MODELS, ANIMAL; MODELS, BIOLOGICAL;

EID: 3042591658     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451221     Document Type: Review

References (37)

1. Hohlfeld, R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997, 120 (Pt5), 865-916.
2. Bashir, K.; Whitaker, J.N. Current immunotherapy for demyelinating diseases. Arch. Neurol. 2002, 59, 726-731.
3. Steinman, L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999, 24, 511-514.
4. Kuchroo, V.K.; Anderson, A.C.; Waldner, H.; Munder, M.; Bettelli, E.; Nicholson, L.B. T cell responses in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 2002, 20, 101-123.
5. Panitch, H.S.; Hirsch, R.L.; Schindler, J.; Johnson, K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37, 1097-1102.
6. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; McFarland, H.F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
7. Martin, R.; McFarland, H. F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 1995, 32, 121-182.
8. Steinman, L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2, 762-764.
9. Ota, K.; Matsui, M; Milford; E.L.; Mackin, G.A.; Weiner, H.L.; Hafler, D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346, 183-187.
10. Ohashi, T.; Yamamura, T.; Inobe, J.; Kondo, T.; Kunishita, T.; Tabira, T. Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of' PLP95-116 as an HLA-DR2, w15-associated determinant. Int. Immunol. 1995, 7, 1771-1778.
11. Wallstrom, E.; Khademi, M.; Abderson, M.; Weissert, R.; Linington, C.; Olsson, T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2 (15)+ multiple sclerosis. Eur. J. Immunol. 1998, 28, 3329-3335.
12. Chen, L.Z.; Hochwald, G.M.; Huang, C.; Dakin, G.; Tao, H.; Cheng, C.; Simmons, W.J.; Dranoff, G.; Thorbecke, G.J. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc. Natl. Acad. Sci. USA 1998, 95: 12516-12521.
13. Setoguchi, K.; Misaki, Y.; Araki, Y.; Fujio, K.; Kawahata, K.; Kitamura, T.; Yamamoto, K. Antigen-specific T cells transduced with IL-10 ameliorate experimenatlly induced arthritis without imparing the systemic immune response to the antigen. J. Immunol. 2000, 165: 5980-5986.
14. Wekerle, H.; Bradl, M.; Linington, C.; Kaab, G.; Kojima, K. The shaping of the brain-specific T lymphocyte repertoire in the thymus. Immunol. Rev. 1996, 149, 231-243.
15. Bendelac, A.; Rivera, M. N.; Park, S.; Roark, J. H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 1997, 15, 535-562.
16. Godfrey, D. I.; Hammond, K. J.; Poulton, L. D.; Smyth, M. J.; Baxter, A. G. NKT cells: Eacts, functions and fallacies, Immunol. Today 2000, 21, 573-583.
17. + suppressor T cells. J. Exp. Med. 2001, 193, F41-F46.
18. Zhang, B.N.; Yamamura, T.; Kondo, T.; Fujiwara, M.; Tabira, T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186, 1677-1687.
19. Pedotti, R.; Mitchell, D.; Wedermeyer, J.; Karpuj, M.; Chabas, D.; Hattab, E.M.; Tsai, M.; Galli, S.J.; Steinman, L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2001, 2, 216-222.
20. Wilson, S. B.; Kent, S. C.; Patton, K. T.; Orban, T.; Jackson, R. A.; Exley, M.; Porcelli, S.; Schatz, D. A.; Atkinson, M. A.; Balk, S. P.; Strominger, J. L.; Hafler, D. A. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 1999, 391, 177-181.
21. Illés, Z.; Kondo, T.; Newcombe, J.; Oka, N.; Tabira, T.; Yamamura, T. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 2000, 164, 4375-4381.
22. Kronenberg, M.; Gapin, L. The unconventional lifestyle of NKT cells. Nat. Immunol. 2002, 2, 557-568.
23. Kawano, T.; Cui, J.; Koezuka, Y.; Toura, I.; Kaneko, Y.; Motoki, K.; Ueno, H.; Nakagawa, R.; Sato, H.; Kondo, E.; Koseki, H.; Taniguchi, M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997, 278, 1626-1629.
24. Brossay, L.; Naidenko, O.; Burdin, N.; Matsuda, J.; Sakai, T.; Kronenberg, M. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J. Immunol. 1998, 161, 5124-5128.
25. Brossay, L.; Chioda, M.; Burdin, N.; Koezuka, Y.; Casorati, G.; Dellabona, P.; Kronenberg, M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 1998, 188, 1521-1528.
26. Spada, F.M.; Koezuka, Y.; Porcelli, S.A. CD1d-restricted recognition of a synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 1998, 188, 1529-1534.
27. Schofield, L.; McConville, M.J.; Hansen, D.; Campbell, A.S.; Fraser-Reid, B.; Grusby, M.J.; Tachado, S.D. CD1d-rectricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999, 283, 225-229.
28. Gumperz, J.E.; Roy, C.; Makowska, A.; Lum, D.; Sugita, M.; Podrebarac, T.; Koezuka, Y.; Porcelli, S.A.; Cardell, S.M.; Brenner, M.B.; Behar, S.M. Murine CD1d-restricted T cell recognition of cellular lpids. Immunity 2000, 12, 211-221.
29. Pál, E.; Tabira, T.; Kawano, T.; Taniguchi, M.; Miyake, S.; Yamamura, T. Costimulation-dependent modulation of experimental autoimmune encephalomylieits by ligand stimulation of Vα14 NKT cells. J. Immunol. 2001, 166, 662-668.
30. Windhagen, A.; Scholz, C.; Hollsberg, P.; Fukaura, H.; Sette, A.; Hafler, D.A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995, 2, 373-380.
31. Moody, D.B.; Besra, G.S.; Wilson, I.A.; Porcelli, S.A. The molecular basis of CD1-mediated presentation of lipid antigens. Immunol. Rev. 1999, 172, 285-296.
32. Miyamoto, K.; Miyake, S.; Yamamura, T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001, 413, 531-534.
33. Wang, B.; Geng, Y. B.; Wang, C. R. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 2001, 194, 313-320.
34. Hong, S.; Wilson, M. T.; Serizawa, I.; Wu, L.; Singh, N.; Naidenko, O. V.; Miura, T.; Haba, T.; Scherer, D. C.; Wei, J.; Koronenberg, M.; Koezuka, Y.; van Kaer, L. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001, 7, 1052-1056.
35. Sharif, S.; Arreaza, G. A.; Zucker, P.; Mi, Q. S.; Sondhi, J.; Naidenko, O. V.; Kronenberg, M.; Koezuka, Y.; Delovitch, T. L.; Gombert, J. M.; Leite-De-Moraes, M.; Gouarin, C.; Zhu, R.; Hameg, A.; Nakayama, T.; Taniguchi, M.; Lepault, F.; Lehuen, A.; Bach, J. F.; Herbelin, A. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 2001, 7, 1057-1062.
36. Jahng, A.W.; Maricic, I.; Pedersen, B.; Burdin, N.; Naidenko, O.; Kronenberg, M.; Koezuka, Y.; Kumar, V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 194, 1789-1799.
37. Singh, A.K.; Wilson, M.T.; Hong, S.; Olivares-Villagomez, D.; Du, C.; Stanic, A.K.; Joyce, S.; Sriram, S.; Koezuka, Y.; Van Kaer, L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 194, 1801-1811.